Updated:
ATEM Capital
ATEM Capital invests in innovations across the Life Sciences industry with the promise to cure once-incurable diseases that help people live longer.
ATEM Capital
ATEM Capital invests in innovations across the Life Sciences industry with the promise to cure once-incurable diseases that help people live longer. Target technologies are breakthroughs with unmet clinical need, strong IP protection, and appeal to strategic players. The firm completes transactions in partnerships with leading US and EU venture groups and acts in strategic partnerships with leading venture firms.
General information
Firm type
Private Equity
Year founded
2014
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, United States
Principals
Allan Gobbs
Managing Partner
Elena Maley
Managing Partner
Zakhar Leikin
M.D., Medical Advisor
Ilia Ardabevskii
Principal
Ilya Yasny
Managing Partner
Dmitry Kobyzev
Managing Partner
Sector focus
Frequently asked questions
Does ATEM Capital disclose its assets under management?
ATEM Capital does not publicly disclose its assets under management. No regulatory filings, press releases, or website disclosures provide a current AUM figure. The firm's public footprint offers no basis for an estimate.
Who runs investment decisions at ATEM Capital?
ATEM Capital does not publish a team roster, investment committee details, or biographies of its principals. Its website at www.atemcap.com does not list personnel, and the firm has no known LinkedIn profile. The identities of those making investment decisions remain undisclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: